{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-003539","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.318444+00:00","generated_at":"2026-06-27T09:49:07.442434+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"low","headline":"Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track","bullets":["New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.","OT-101 program on track to be fully funded by JV for re-IPO, per filing.","No financial figures or milestones disclosed in the 8-K or attached exhibit.","Presentation attached as Exhibit 99.1 but content not available for review."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-003539","json":"https://secwatch.observer/filing/0001493152-22-003539.json","markdown":"https://secwatch.observer/filing/0001493152-22-003539.md","text":"https://secwatch.observer/filing/0001493152-22-003539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/0001493152-22-003539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:49:07.442434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}